CD274 and neoplasm: PD-1/PD-L1 inhibitors restore T-cell function and enhance the cytotoxic activity of T-cells against tumor cells by blocking the interaction between the PD-1 receptor on T-cells and its ligand, PD-L1 (24, 25).